{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ipilimumab&page=27", "query": { "intervention": "ipilimumab", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 640, "total_pages": 64, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ipilimumab&page=28&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ipilimumab&page=26&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T05:44:36.356Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04697576", "title": "Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage I Cutaneous Melanoma AJCC v8", "Clinical Stage IA Cutaneous Melanoma AJCC v8", "Clinical Stage IB Cutaneous Melanoma AJCC v8", "Clinical Stage II Cutaneous Melanoma AJCC v8", "Clinical Stage IIA Cutaneous Melanoma AJCC v8", "Clinical Stage IIB Cutaneous Melanoma AJCC v8", "Clinical Stage IIC Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Quadrivalent Inactivated Influenza Vaccine", "type": "BIOLOGICAL" }, { "name": "Resection", "type": "PROCEDURE" }, { "name": "Nivolumab + Relatlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Carlo Contreras", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 36, "start_date": "2021-10-20", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-29T05:44:36.356Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04697576" }, { "nct_id": "NCT07155317", "title": "Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Acral Melanoma", "Advanced Cutaneous Melanoma", "Advanced Mucosal Melanoma", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Acral Melanoma", "Metastatic Cutaneous Melanoma", "Metastatic Mucosal Melanoma", "Unresectable Acral Melanoma", "Unresectable Cutaneous Melanoma", "Unresectable Mucosal Melanoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2025-10-29", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-29T05:44:36.356Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07155317" }, { "nct_id": "NCT01515189", "title": "Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 831, "start_date": "2012-02-17", "completion_date": "2017-08-17", "has_results": true, "last_update_posted_date": "2019-07-31", "last_synced_at": "2026-10-29T05:44:36.356Z", "location_count": 11, "location_summary": "Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01515189" }, { "nct_id": "NCT02488759", "title": "An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Various Advanced Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Relatlimab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 578, "start_date": "2015-10-13", "completion_date": "2022-10-24", "has_results": true, "last_update_posted_date": "2023-11-13", "last_synced_at": "2026-10-29T05:44:36.356Z", "location_count": 14, "location_summary": "Tampa, Florida • Atlanta, Georgia • Lutherville, Maryland + 9 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Lutherville", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02488759" }, { "nct_id": "NCT01729806", "title": "Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CD20 Positive", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2012-11-19", "completion_date": "2018-03-30", "has_results": false, "last_update_posted_date": "2018-04-11", "last_synced_at": "2026-10-29T05:44:36.356Z", "location_count": 7, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01729806" }, { "nct_id": "NCT01950390", "title": "Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Unresectable Melanoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2014-01-24", "completion_date": "2025-01-31", "has_results": true, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-10-29T05:44:36.356Z", "location_count": 482, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 298 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01950390" }, { "nct_id": "NCT04840589", "title": "Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Solid Neoplasm", "Recurrent Malignant Solid Neoplasm", "Recurrent Platinum-Resistant Ovarian Carcinoma", "Refractory Ovarian Carcinoma" ], "interventions": [ { "name": "BET Bromodomain Inhibitor ZEN-3694", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2022-02-02", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-29T05:44:36.356Z", "location_count": 9, "location_summary": "Bethesda, Maryland • New York, New York • The Bronx, New York + 3 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04840589" }, { "nct_id": "NCT06630429", "title": "A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-Small Cell Lung Cancer", "Renal Cell Carcinoma (RCC)" ], "interventions": [ { "name": "Biospecimen Collection", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2020-09-02", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-29T05:44:36.356Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630429" }, { "nct_id": "NCT05700461", "title": "Drug Screening Using Novel IMD in Renal Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma", "Metastatic Renal Cell Carcinoma", "Kidney Cancer" ], "interventions": [ { "name": "Implantable Microdevice (IMD)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Oliver Jonas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-12-01", "completion_date": "2029-08-31", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-10-29T05:44:36.356Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05700461" }, { "nct_id": "NCT01714739", "title": "A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "CANCER,NOS" ], "interventions": [ { "name": "Lirilumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 337, "start_date": "2012-10-07", "completion_date": "2019-12-13", "has_results": true, "last_update_posted_date": "2023-02-02", "last_synced_at": "2026-10-29T05:44:36.356Z", "location_count": 16, "location_summary": "San Francisco, California • Ocala, Florida • Chicago, Illinois + 11 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Ocala", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lutherville", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01714739" } ] }